Cargando…

Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

OBJECTIVE: Recent clinical trials targeting amyloid beta (Aβ) and tau in Alzheimer's disease (AD) have yet to demonstrate efficacy. Reviewing the hypotheses for AD pathogenesis and defining possible links between them may enhance insights into both upstream initiating events and downstream mech...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xu‐Qiao, Salehi, Ahmad, Pearn, Matthew L., Overk, Cassia, Nguyen, Phuong D., Kleschevnikov, Alexander M., Maccecchini, Maria, Mobley, William C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Theoretical Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984396/ https://www.ncbi.nlm.nih.gov/pubmed/32975365 http://dx.doi.org/10.1002/alz.12185

Ejemplares similares

Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse
por: Teich, Andrew F., et al.
Publicado: (2018)

Pathological trajectory in the Ts65Dn model of Down syndrome
por: Tallino, Savannah, et al.
Publicado: (2023)

Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Giacomini, Andrea, et al.
Publicado: (2015)

Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2017)

Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
por: Kirstein, Martina, et al.
Publicado: (2022)

Breathing and Oxygen Carrying Capacity in Ts65Dn and Down Syndrome
por: DeRuisseau, Lara R, et al.
Publicado: (2023)

Deleterious Effects of Chronic Folate Deficiency in the Ts65Dn Mouse Model of Down Syndrome
por: Helm, Susan, et al.
Publicado: (2017)

Modeling Alzheimer’s disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior
por: Overk, Cassia, et al.
Publicado: (2023)

Increased male reproductive success in Ts65Dn “Down syndrome” mice
por: Moore, Clara S., et al.
Publicado: (2010)

Digastric Muscle Phenotypes of the Ts65Dn Mouse Model of Down Syndrome
por: Glass, Tiffany J., et al.
Publicado: (2016)

Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome
por: Lysenko, Larisa V., et al.
Publicado: (2014)

Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome
por: Simoes de Souza, Fabio M., et al.
Publicado: (2011)

Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome
por: Marland, Jamie R. K., et al.
Publicado: (2016)

Hypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis
por: López-Hidalgo, Rosa, et al.
Publicado: (2016)

Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Zhou, Wen-Bo, et al.
Publicado: (2019)

Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome
por: Duchon, Arnaud, et al.
Publicado: (2011)

The Adult Ts65Dn Mouse Model of Down Syndrome Shows Altered Swallow Function
por: Glass, Tiffany J., et al.
Publicado: (2019)

Glutamatergic synaptic deficits in the prefrontal cortex of the Ts65Dn mouse model for Down syndrome
por: Thomazeau, Aurore, et al.
Publicado: (2023)

Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression
por: Chen, Xu-Qiao, et al.
Publicado: (2021)

Altered intrinsic and network properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome
por: Cramer, Nathan P., et al.
Publicado: (2015)

Protein Dynamics Associated with Failed and Rescued Learning in the Ts65Dn Mouse Model of Down Syndrome
por: Ahmed, Md. Mahiuddin, et al.
Publicado: (2015)

Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome
por: Gómez de Salazar, Macarena, et al.
Publicado: (2018)

Spatiotemporal development of spinal neuronal and glial populations in the Ts65Dn mouse model of Down syndrome
por: Aziz, Nadine M., et al.
Publicado: (2019)

Signalling pathways contributing to learning and memory deficits in the Ts65Dn mouse model of Down syndrome
por: Freeburn, Aimée, et al.
Publicado: (2021)

Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome
por: Fulton, Sasha L., et al.
Publicado: (2022)

Effects of Neonatal Neural Progenitor Cell Implantation on Adult Neuroanatomy and Cognition in the Ts65Dn Model of Down Syndrome
por: Rachubinski, Angela L., et al.
Publicado: (2012)

Longitudinal neuroanatomical and behavioral analyses show phenotypic drift and variability in the Ts65Dn mouse model of Down syndrome
por: Shaw, Patricia R., et al.
Publicado: (2020)

A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome
por: Chen, Xu-Qiao
Publicado: (2021)

Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome
por: Usowicz, Maria M., et al.
Publicado: (2012)

Heart rate and blood pressure in male Ts65Dn mice: a model to investigate cardiovascular responses in Down syndrome
por: DeRuisseau, Lara R., et al.
Publicado: (2019)

Evidence of Energy Metabolism Alterations in Cultured Neonatal Astrocytes Derived from the Ts65Dn Mouse Model of Down Syndrome
por: Zampieri, Bruna L., et al.
Publicado: (2022)

Physical Training Chronically Stimulates the Motor Neuron Cell Nucleus in the Ts65Dn Mouse, a Model of Down Syndrome
por: Inguscio, Chiara Rita, et al.
Publicado: (2023)

Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
por: Scott-McKean, Jonah J., et al.
Publicado: (2018)

Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
por: Kazim, Syed Faraz, et al.
Publicado: (2017)

Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome
por: Tsuji, Masahiro, et al.
Publicado: (2020)

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome
por: Puente-Bedia, Alba, et al.
Publicado: (2022)

Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome
por: Aziz, Nadine M., et al.
Publicado: (2018)

Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer’s Related Pathological Changes in Down Syndrome
por: DeCourt, Boris, et al.
Publicado: (2013)

Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2013)

Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging
por: Duval, Nathan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7lh149snntf9gpssl1t3vfodmd